Will GSK’s China Scandals Diminish Big Pharma’s Interest in China R&D?
publication date: Jul 12, 2013
Because of scandals in China – first a retraction of a scientific article, then the bribery accusations – GlaxoSmithKline’s China operations have cast a pall over the entire company’s reputation. An even larger question is whether the company’s problems will spill over to affect other multinational pharmas that are also operating in China. In particular, will Glaxo’s misfortunes deal a blow to R&D in China? According to Greg B. Scott, CEO of ChinaBio®, "If something like the scientific retraction had occurred in the US or Europe, the company involved would just have said that a researcher made an error,” Scott said. “But it happened in China, so it affects the perception of the whole country." More details....
Stock Symbol: (NYSE: GSK)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.